Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough

KENILWORTH, N.J.--(BUSINESS WIRE)-- March 17, 2020 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced top-line efficacy results from two ongoing pivotal Phase 3 t

Latest News Clinical News 853
Read All

Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine

Tuesday, March 17, 2020 - NEW YORK & MAINZ, Germany--(BUSINESS WIRE) -- Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the companies have agreed

Latest News Clinical News 789
Read All

Regeneron Announces Important Advances in Novel COVID-19 Antibody Program

TARRYTOWN, N.Y., March 17, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the latest progress in its efforts to discover and develop a novel multi-antibody cocktai

Latest News Clinical News 853
Read All

NIH Clinical Trial of Investigational Vaccine for COVID-19 Begins in Seattle

March 16, 2020 -- A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Resear

Latest News Clinical News 830
Read All

Sanofi and Regeneron Begin Global Kevzara® (sarilumab) Clinical Trial Program in Patients with Severe COVID-19

CAMBRIDGE, Mass. and TARRYTOWN, N.Y., March 16, 2020 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc today announced they have started a clinical program evaluating Kevzara® (sarilumab) in p

Latest News Clinical News 947
Read All

Johnson & Johnson Announces Collaboration with the Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine Development

NEW BRUNSWICK, N.J., March 13, 2020 -- Johnson & Johnson today announced that its Janssen Pharmaceutical Companies have entered a collaboration with the Beth Israel Deaconess Medical Center (BIDMC

Latest News Clinical News 768
Read All

FDA Approves Monjuvi (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Print this page

PLANEGG/MUNICH, Germany - August 1, 2020 and WILMINGTON, Del. - July 31, 2020 -- MorphoSys AG NASDAQ:MOR) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has

Latest News NDA News 1102
Read All

Update on Phase III GY004 Trial for Cediranib Added to Lynparza in Platinum-Sensitive Relapsed Ovarian Cancer

12 March 2020 -- AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced high-level results from the Phase III GY004 trial, led by

Latest News Clinical News 1184
Read All

New Clinical Study Data for Gilead’s Investigational HIV-1 Capsid Inhibitor GS-6207 Presented at CROI 2020

BOSTON--(BUSINESS WIRE) March 11, 2020 -- Gilead Sciences, Inc. (NASDAQ: GILD) today announced data from clinical and preclinical studies exploring the use of GS-6207, an investigational, novel, first

Latest News Clinical News 796
Read All

Treatment With Gilead’s Vesatolimod Is Evaluated for Safety and Virologic and Immunologic Response Versus Placebo in Phase 1B HIV Functional Cure Study

BOSTON--(BUSINESS WIRE) March 10, 2020 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from a Phase 1b trial evaluating the company’s investigational toll-like receptor 7 (TLR7) agonis

Latest News Clinical News 801
Read All

Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for JNJ-6372 for the Treatment of Non-Small Cell Lung Cancer

RARITAN, NJ, March 10, 2020 -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designati

Latest News Clinical News 839
Read All

FDA Approves Tecartus (brexucabtagene autoleucel) as the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma

SANTA MONICA, Calif.--(BUSINESS WIRE)--Jul. 24, 2020 -- Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Teca

Latest News NDA News 1179
Read All
News
- CLINIEXPERT -
Int'l Clinical Service Expert

We are the leader
Because of our professionism